LXEO Lexeo Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907108 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.3%
TTM EPS YoY54.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-62.4%
ROA-54.3%
ROIC (approx.)-88.6%
Asset turnover—
Leverage & solvency
Liabilities / assets11.2%
Debt / equity0.00x
Current ratio8.69x
Interest coverage-1,807.43x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $34.50M | $19.03M | $15.70M | $16.21M | $15.70M | $14.72M | $17.17M | $18.37M |
| SG&A expense | $5.90M | $8.99M | $6.63M | $6.91M | $5.95M | $15.97M | $16.63M | $9.02M |
| Operating income | -$40.40M | -$28.02M | -$22.33M | -$23.12M | -$21.65M | -$30.69M | -$33.80M | -$27.38M |
| Interest expense | $12,000 | $14,000 | $17,000 | $20,000 | $22,000 | $25,000 | $28,000 | $30,000 |
| Pretax income | -$38.30M | -$25.87M | -$20.20M | -$20.63M | -$20.28M | -$26.10M | -$32.66M | -$25.92M |
| Net income | -$38.30M | -$25.87M | -$20.20M | -$20.92M | -$20.28M | -$26.10M | -$32.66M | -$25.92M |
| EBITDA | -$40.31M | -$27.95M | -$22.26M | -$23.04M | -$21.57M | -$30.63M | -$33.74M | -$27.31M |
| EPS (basic) | -0.43 | -0.30 | -0.25 | — | -0.33 | -0.60 | -0.99 | — |
| EPS (diluted) | -0.43 | -0.30 | -0.25 | — | -0.33 | -0.60 | -0.99 | — |
| Weighted avg. shares (diluted) | 88.68M | 85.63M | 81.18M | — | 60.98M | 43.57M | 33.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $90.22M | $92.83M | $71.77M | $63.00M | $44.24M | $38.73M | $32.16M | $38.27M |
| Short-term investments | $104.56M | $118.87M | $121.28M | $118.77M | $81.77M | $97.41M | $70.92M | $86.50M |
| Current assets | $204.93M | $217.91M | $200.86M | $188.39M | $127.79M | $140.06M | $105.27M | $126.12M |
| PP&E, net | $1.73M | $1.12M | $1.10M | $1.14M | $1.23M | $1.11M | $1.04M | $1.03M |
| Total assets | $243.92M | $254.90M | $250.36M | $268.69M | $143.84M | $176.07M | $125.69M | $146.94M |
| Current liabilities | $23.59M | $15.69M | $14.19M | $16.81M | $17.27M | $31.59M | $30.82M | $22.85M |
| Total liabilities | $27.23M | $19.84M | $18.86M | $22.02M | $23.01M | $37.85M | $37.58M | $30.10M |
| Shareholders' equity | $216.69M | $235.06M | $231.50M | $246.67M | $120.83M | $138.22M | $88.11M | $116.84M |
| Shares outstanding | 82.79M | 78.62M | 74.09M | 73.00M | 54.93M | 54.00M | 33.19M | 33.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.56M | -$17.60M | -$21.14M | -$20.08M | -$29.55M | -$27.22M | -$21.72M | -$28.33M |
| Capital expenditure | $298,000 | $7,000 | $35,000 | $0 | $289,000 | — | — | $0 |
| Free cash flow | -$28.86M | -$17.60M | -$21.18M | -$20.08M | -$29.84M | — | — | -$28.33M |
| Investing cash flow | $11.92M | $14.26M | $27.46M | -$101.69M | $35.01M | -$39.17M | $15.60M | -$93.58M |
| Financing cash flow | $14.03M | $24.40M | $2.45M | $143.77M | $52,000 | $72.96M | $11,000 | -$97,000 |
| Depreciation & amortization | $86,000 | $74,000 | $73,000 | $73,000 | $73,000 | $62,000 | $60,000 | $75,000 |
| Stock-based compensation | $3.69M | $5.69M | $2.75M | $2.71M | $2.65M | $3.07M | $3.70M | $3.51M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.